We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear

By LabMedica International staff writers
Posted on 30 Jun 2025

Preeclampsia, a pregnancy-related complication characterized by elevated blood pressure and organ dysfunction, remains a major contributor to maternal and infant health issues globally. More...

Existing screening techniques in the first trimester rely primarily on maternal risk indicators or placental biomarkers, but these methods fail to detect over half of the cases and frequently identify risk only after the condition has already begun to develop. New findings presented at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveal that a straightforward blood test conducted during the first trimester may accurately flag women at risk of developing preeclampsia up to five months before a clinical diagnosis is made.

Researchers from the Carlos Simon Foundation (Valencia, Spain) and iPremom (Valencia, Spain) employed a cell-free RNA (cfRNA) “liquid biopsy” of maternal plasma to carry out the study. Between September 2021 and June 2024, 9,586 pregnant individuals from 14 hospitals in Spain participated. In a nested case-control study involving 216 participants, the team was able to successfully forecast both early-onset and late-onset forms of preeclampsia well ahead of symptom manifestation. The cfRNA methodology captures nuanced molecular cues from multiple maternal sources, such as the uterus and placenta, long before symptoms develop. According to findings published in Human Reproduction, blood was drawn during three different pregnancy stages (9–14 weeks, 18–28 weeks, and beyond 28 weeks or at diagnosis). cfRNA was extracted from 548 plasma samples taken from the 216 selected individuals and analyzed using Illumina sequencing technology. Researchers applied machine learning techniques to identify cfRNA “signatures” that could forecast the later development of preeclampsia.

In the first trimester, the cfRNA-based model achieved an 83% sensitivity and 90% specificity in predicting early-onset preeclampsia (EOPE), with an average lead time of 18 weeks before diagnosis and an AUC of 0.88. Notably, 47.2% of the predictive transcripts were associated with genes related to the maternal endometrium, particularly those involved in decidualization resistance—a failure of the uterine lining to adapt properly in early pregnancy. These findings bolster the idea that uterine dysfunction is a significant contributor to EOPE. Late-onset preeclampsia (LOPE) was also forecasted using a different cfRNA signature, approximately 14.9 weeks before clinical onset, and shared minimal transcript overlap with the EOPE profile. Unlike EOPE, the LOPE markers contained few decidualization-related genes and instead reflected broader systemic biological changes. This distinction affirms that EOPE and LOPE are biologically and temporally separate disorders.

“We are currently conducting a prospective clinical study designed to validate the utility and feasibility of cfRNA screening in standard prenatal care,” said project leader Dr. Tamara Garrido. “With validation and regulatory efforts already underway, we anticipate that cfRNA-based screening could become available in clinical practice within the next year, offering an unprecedented opportunity for early, non-invasive identification of high-risk pregnancies and timely intervention.”

Related Links:
Carlos Simon Foundation
iPremom


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.